# Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics
Canonical URL: https://biopharmsignal.com/news/TNYA/tenaya-therapeutics-enters-into-research-collaboration-with-alnylam-pharmaceuticals-to-identify-and-validate-novel-genetic-targets-for-cardiovascular-disease-therapeutics
Ticker: TNYA
Company: Tenaya Therapeutics
Source: Tenaya Therapeutics
Published: 2026-03-05 13:30 EST
Original Source URL: https://investors.tenayatherapeutics.com
## Summary

Agreement Combines Tenaya’s Expertise in Identification and Validation of Genetic Heart Disease Targets with Alnylam’s Ability to Deliver Transformational Therapeutics Tenaya to Receive Up to $10 Million in Upfront Payments in Addition to Research Funding and Milestone Payments of Up to $1.13

## Article Body
Agreement Combines Tenaya’s Expertise in Identification and Validation of Genetic Heart Disease Targets with Alnylam’s Ability to Deliver Transformational Therapeutics Tenaya to Receive Up to $10 Million in Upfront Payments in Addition to Research Funding and Milestone Payments of Up to $1.13
## Recent Company News
- 2026-06-03 11:00 EST — [Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms](https://biopharmsignal.com/news/TNYA/tenaya-therapeutics-announces-interim-data-from-mypeaktm-1-showing-treatment-of-mybpc3-associated-hcm-with-tn-201-gene-therapy-resulted-in-consistent-signs-of-cardiac-remodeling-and-reductions-in-symptoms) — Source: Tenaya Therapeutics
- 2026-06-02 20:30 EST — [Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026](https://biopharmsignal.com/news/TNYA/tenaya-therapeutics-to-announce-new-interim-data-from-mypeaktm-1-phase-1b-2-trial-of-tn-201-for-adults-with-mybpc3-associated-hcm-on-wednesday-june-3-2026) — Source: Tenaya Therapeutics
- 2026-05-29 12:00 EST — [Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026](https://biopharmsignal.com/news/TNYA/tenaya-therapeutics-to-participate-in-the-jefferies-global-healthcare-conference-2026) — Source: Tenaya Therapeutics
- 2026-05-15 10:01 EST — [Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC](https://biopharmsignal.com/news/TNYA/positive-interim-data-from-cohorts-1-and-2-of-tenaya-s-ridgetm-1-phase-1b-2-clinical-trial-of-tn-401-demonstrated-consistent-reductions-in-arrhythmia-burden-for-adults-with-pkp2-associated-arvc) — Source: Tenaya Therapeutics
- 2026-05-06 20:05 EST — [Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/TNYA/tenaya-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Tenaya Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)